Reduced POLD3 Expression Induces DNA Damage and Telomere Shortening in Colorectal Cancer Cells: A Potential Mediator of Colorectal Cancer Risk Variants
This study demonstrates that reduced POLD3 expression in colorectal cancer cells induces DNA damage, telomere shortening, and cell cycle arrest, providing a functional mechanism for how POLD3 locus risk variants contribute to colorectal cancer development and prognosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every cell in the human body carries a complete set of instructions for building and maintaining a living organism, written in a molecule called DNA. To keep these instructions readable and intact, cells must constantly copy them as they divide and repair them when they are damaged. This process relies on a team of molecular machines, including a complex known as DNA polymerase delta, which acts like a high-precision editor and copyist. If this machine falters, the instructions can become garbled, leading to mutations that may eventually cause cancer. For years, scientists have known that certain variations in our genetic code, found near the gene that helps build this editing machine, are linked to a higher risk of developing colorectal cancer. However, knowing that a link exists is different from understanding why it happens. The question has remained: how does a small change in the amount of this specific protein actually influence the health of a cell and the development of disease?
A team of researchers set out to answer this by looking directly at what happens inside colorectal cancer cells when the levels of the POLD3 protein are reduced. POLD3 is a crucial component of the DNA editing machine, helping it stay together and attach to the DNA strand it is copying. The scientists began by examining data from hundreds of patients with colorectal cancer. They found that patients whose tumors had lower levels of this protein tended to have poorer survival outcomes, a trend that was especially clear in a specific group of tumors that did not have defects in their mismatch repair system. This observation suggested that having less of this protein might be harmful, but to understand the mechanism, the researchers needed to watch the process in action.
To see the effects of low POLD3 levels, the team created laboratory models using two well-known types of colorectal cancer cells. They introduced a tool that allowed them to turn down the production of the POLD3 protein, effectively creating cells with less of this essential component. As they expected, these cells grew more slowly than normal cells. When the researchers checked the cell cycle, they saw that the cells were getting stuck in the middle of their division process, unable to finish copying their DNA. This stalling led to a significant increase in cell death, as the cells could not cope with the stress of incomplete replication.
The most critical discovery, however, concerned the integrity of the DNA itself. When the POLD3 protein was reduced, the cells accumulated a dangerous type of damage known as double-strand breaks, where the DNA molecule is severed completely in two places. Normally, cells have repair systems to fix these breaks, and the researchers observed that the cells tried to activate these repair pathways. Yet, despite the repair machinery working harder, the damage persisted. The cells also showed signs of increased stress and instability, indicating that the reduced amount of POLD3 was preventing the DNA from being copied and repaired correctly, leaving the genome vulnerable.
The study also uncovered a surprising effect on the ends of the chromosomes, known as telomeres. These structures act like protective caps that prevent the DNA from fraying, and cancer cells usually find ways to keep them long so they can divide indefinitely. The researchers found that when POLD3 levels dropped, the telomeres in these cancer cells became significantly shorter. This shortening occurred even though the cells tried to compensate by increasing the production of a protein called TERT, which is usually responsible for lengthening telomeres. The evidence pointed to a specific failure in an alternative method cells use to maintain their telomeres, a process that relies heavily on the POLD3 protein. Without enough POLD3, this backup system failed, and the protective caps wore down.
These findings suggest a clear chain of events: a reduction in the POLD3 protein leads to a failure in DNA copying and repair, which causes breaks in the genetic code and shortens the protective caps on chromosomes. This accumulation of damage creates a state of genetic instability that can drive cancer progression and lead to worse outcomes for patients. The research provides a functional explanation for why certain genetic variations near the POLD3 gene are linked to higher cancer risk; these variations likely result in slightly lower levels of the protein, which in turn allows damage to build up over time. While the study was conducted in laboratory cell lines and does not yet prove how this plays out in every human patient, it offers a concrete biological story for how a small genetic difference can tip the balance toward disease, highlighting the delicate precision required to maintain the integrity of our genetic code.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.